华兰疫苗
(301207)
| 流通市值：101.99亿 | | | 总市值：102.05亿 |
| 流通股本：6.01亿 | | | 总股本：6.01亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 373,561,360.33 | 352,938,221.02 | 854,136,140.42 | 582,404,049.57 |
| 交易性金融资产 | 2,190,377,717.05 | 1,973,244,813.4 | 1,534,320,013.96 | 1,439,121,426.67 |
| 应收票据及应收账款 | 1,187,144,328.64 | 1,347,946,633.85 | 1,347,999,845.61 | 938,316,480.99 |
| 应收账款 | 1,187,144,328.64 | 1,347,946,633.85 | 1,347,999,845.61 | 938,316,480.99 |
| 应收款项融资 | 3,368,444.05 | 1,359,480 | 454,100 | 440,000 |
| 预付款项 | 37,706,413.99 | 14,639,543.6 | 30,829,996.24 | 27,517,188.98 |
| 其他应收款合计 | 166,904.35 | 12,781.23 | 569,225.32 | 437,005.38 |
| 存货 | 262,619,953.62 | 179,202,075.56 | 269,422,430.02 | 381,020,418.21 |
| 一年内到期的非流动资产 | 184,785,832.22 | 358,444,586.99 | 687,175,666.67 | 1,044,459,500 |
| 其他流动资产 | 219,403,103.43 | 155,368,591.41 | 55,172,759.47 | 55,989,398.04 |
| 流动资产合计 | 4,459,134,057.68 | 4,383,156,727.06 | 4,780,080,177.71 | 4,469,705,467.84 |
| 非流动资产: | | | | |
| 固定资产 | 898,218,583.7 | 932,405,912.18 | 962,788,496.74 | 996,094,366.85 |
| 在建工程 | 10,274,712.72 | 10,274,712.72 | 7,317,326.22 | 7,297,946.22 |
| 生产性生物资产 | 363,576.17 | 1,030,354.18 | 1,398,553.37 | 523,090.71 |
| 无形资产 | 19,888,610.95 | 20,087,307.81 | 20,286,004.66 | 20,484,701.52 |
| 开发支出 | 27,926,627.87 | 27,923,495 | 27,867,304 | 27,864,900.22 |
| 递延所得税资产 | 185,955,958.27 | 189,060,594.68 | 204,762,701.06 | 222,514,515.45 |
| 其他非流动资产 | 1,237,464,866.76 | 1,280,322,942.48 | 1,174,869,156.97 | 1,167,910,748.58 |
| 非流动资产合计 | 2,380,092,936.44 | 2,461,105,319.05 | 2,399,289,543.02 | 2,442,690,269.55 |
| 资产总计 | 6,839,226,994.12 | 6,844,262,046.11 | 7,179,369,720.73 | 6,912,395,737.39 |
| 流动负债: | | | | |
| 短期借款 | - | - | - | 0 |
| 应付票据及应付账款 | 71,248,528.42 | 60,977,711.18 | 73,366,553.15 | 87,272,664.14 |
| 其中：应付票据 | - | 8,485,471.65 | 20,490,973.73 | 12,005,502.08 |
| 应付账款 | 71,248,528.42 | 52,492,239.53 | 52,875,579.42 | 75,267,162.06 |
| 合同负债 | 3,837,984.91 | 3,596,228.79 | 4,590,561.64 | 18,935,645.18 |
| 应付职工薪酬 | - | - | - | 0 |
| 应交税费 | 202,683.96 | 3,960,504.82 | 6,258,335.68 | 1,425,288.49 |
| 其他应付款合计 | 935,915,451.38 | 983,384,644.97 | 1,380,007,326.04 | 841,598,874.66 |
| 应付股利 | - | - | 367,800,019.8 | 91,800,000 |
| 其他流动负债 | 64,471,784.99 | 65,099,564.98 | 137,674.31 | 565,866.78 |
| 流动负债合计 | 1,075,676,433.66 | 1,117,018,654.74 | 1,464,360,450.82 | 949,798,339.25 |
| 非流动负债: | | | | |
| 递延收益 | 21,895,258.56 | 22,953,802.22 | 24,012,345.88 | 25,070,889.54 |
| 递延所得税负债 | - | - | 16,155,280.53 | 18,992,471.2 |
| 非流动负债合计 | 21,895,258.56 | 22,953,802.22 | 40,167,626.41 | 44,063,360.74 |
| 负债合计 | 1,097,571,692.22 | 1,139,972,456.96 | 1,504,528,077.23 | 993,861,699.99 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 601,027,500 | 601,027,500 | 601,027,500 | 601,027,500 |
| 资本公积 | 2,910,330,349.84 | 2,910,330,349.84 | 2,931,493,494.98 | 2,929,697,312.33 |
| 减:库存股 | 106,786,852.51 | 106,786,852.51 | 106,786,852.51 | 106,786,852.51 |
| 盈余公积 | 300,513,750 | 300,513,750 | 300,513,750 | 300,513,750 |
| 未分配利润 | 2,036,570,554.57 | 1,999,204,841.82 | 1,948,593,751.03 | 2,194,082,327.58 |
| 归属于母公司股东权益合计 | 5,741,655,301.9 | 5,704,289,589.15 | 5,674,841,643.5 | 5,918,534,037.4 |
| 股东权益合计 | 5,741,655,301.9 | 5,704,289,589.15 | 5,674,841,643.5 | 5,918,534,037.4 |
| 负债和股东权益合计 | 6,839,226,994.12 | 6,844,262,046.11 | 7,179,369,720.73 | 6,912,395,737.39 |
| 公告日期 | 2026-04-27 | 2026-03-28 | 2025-10-30 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |